Last reviewed · How we verify

NCT05590715

International Multicentric Observational Study to Characterize Subpopulations of Patients With Autism Spectrum Disorder

Recruiting now Last updated 17 June 2025
What this trial tests

trial in Autism Spectrum Disorder in 1,500 participants. Currently enrolling.

Timeline
13 October 2022
Primary endpoint
31 December 2025
31 December 2025

Quick facts

Lead sponsorStalicla SA
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment1,500
Start date13 October 2022
Primary completion31 December 2025
Estimated completion31 December 2025
Sites21 locations across United States, Australia, Spain

Conditions studied

Sponsor

Stalicla SA — full company profile →

Who can join

Adults 12 to 65, any sex, with Autism Spectrum Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine sufficient number of biological and clinical markers to identify subgroups of potential best responders to a specific medication

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Autism Spectrum Disorder

Currently open trials in the same condition.

Other Stalicla SA trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05590715.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing